Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 1/20 | 0.61 |
| ▸ | NPY2R | P49146 | 1/20 | 0.61 |
| ▸ | NPY4R | P50391 | 1/20 | 0.61 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.61 |
| ▸ | GLP1R | P43220 | 13/20 | 0.57 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.55 |
| ▸ | GCGR | P47871 | 5/20 | 0.55 |
| ▸ | GIPR | P48546 | 2/20 | 0.55 |
| ▸ | CALCA | P06881 | 1/20 | 0.55 |
| ▸ | ECE1 | P42892 | 1/20 | 0.54 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13613774 | 0.87 | GALR2 (0.59) | GLP1RGIPRCALCA | |
| SCHEMBL29370578 | 0.86 | NPY1R (0.67) | NPY1RNPY2RNPY4RNPY5RGLP1R | |
| SCHEMBL29972944 | 0.85 | NPY1R (0.69) | NPY1RNPY2RNPY4RNPY5RGLP1R | |
| SCHEMBL29851285 | 0.85 | CXCR4 (0.64) | NPY1RNPY2RNPY4RNPY5RGLP1R | |
| SCHEMBL30973903 | 0.84 | NPY1R (0.66) | NPY1RNPY2RNPY4RNPY5RGLP1R | |
| SCHEMBL30906424 | 0.84 | NPY2R (0.70) | NPY1RNPY2RNPY4RNPY5RGLP1R | |
| Galanin SCHEMBL29352997 | 0.84 | GLP1R (0.67) | NPY1RNPY2RNPY4RNPY5RGLP1R | |
| SCHEMBL30666385 | 0.83 | NPY1R (0.69) | NPY1RNPY2RNPY4RNPY5RGLP1R | |
| SCHEMBL29972984 | 0.83 | NPY1R (0.65) | NPY1RNPY2RNPY4RNPY5RGLP1R | |
| SCHEMBL30041162 | 0.83 | CALCA (0.64) | NPY1RNPY2RNPY4RNPY5RGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113454115-B | Chimeric antigen receptor targeting sialyl lewis a and uses thereof | 纪念斯隆-凯特琳癌症中心 | 2025-06-13 | — | — | CN | claimed |
| CN-119019572-A | Enhanced chimeric antigen receptor and uses thereof | 纪念斯隆-凯特琳癌症中心 | 2024-11-26 | — | — | CN | claimed |
| CN-118955737-A | Enhanced chimeric antigen receptor and uses thereof | 纪念斯隆-凯特琳癌症中心 | 2024-11-15 | — | — | CN | claimed |
| US-20240166743-A1 | ENHANCED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2024-05-23 | — | — | US | claimed |
| US-11932690-B2 | Enhanced chimeric antigen receptors and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2024-03-19 | — | — | US | claimed |
| CN-114585641-A | Mesothelin CAR and uses thereof | 纪念斯隆-凯特琳癌症中心 | 2022-06-03 | — | — | CN | claimed |
| US-20220125905-A1 | MESOTHELIN CARS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-04-28 | — | — | US | claimed |
| EP-3969470-A1 | MESOTHELIN CARS AND USES THEREOF | Memorial Sloan Kettering Cancer Center (US) | 2022-03-23 | — | — | EP | claimed |
| EP-4709745-A1 | EXTRACELLULAR VESICLES FOR THE DELIVERY OF PAYLOADS TO EUKARYOTIC CELLS | Alaya.Bio Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4683932-A2 | CELLS AND COMPOSITIONS FOR TREATING CANCER | Memorial Sloan-Kettering Cancer Center (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20260007750-A1 | CELLS AND COMPOSITIONS FOR TREATING CANCER | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2026-01-08 | — | — | US | disclosed |
| CN-113454115-B | Chimeric antigen receptor targeting sialyl lewis a and uses thereof | 纪念斯隆-凯特琳癌症中心 | 2025-06-13 | — | — | CN | disclosed |
| CN-114585641-B | Mesothelin CAR and uses thereof | 纪念斯隆-凯特琳癌症中心 | 2025-05-23 | — | — | CN | disclosed |
| US-20240398866-A1 | CELLS EXPRESSING FAS LIGAND AND CFLIP POLYPEPTIDES AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2024-12-05 | — | — | US | disclosed |
| US-20220401475-A1 | COMBINATIONS OF MULTIPLE CHIMERIC ANTIGEN RECEPTORS FOR IMMUNOTHERAPY | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-12-22 | — | — | US | disclosed |
| CN-115210254-A | Cells expressing C-KIT mutations and uses thereof | 纪念斯隆-凯特琳癌症中心 | 2022-10-18 | — | — | CN | disclosed |
| EP-4069730-A1 | CELLS EXPRESSING C-KIT MUTATIONS AND USES THEREOF | Memorial Sloan Kettering Cancer Center (US) | 2022-10-12 | — | — | EP | disclosed |
| CN-114585641-A | Mesothelin CAR and uses thereof | 纪念斯隆-凯特琳癌症中心 | 2022-06-03 | — | — | CN | disclosed |
| US-20220125905-A1 | MESOTHELIN CARS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-04-28 | — | — | US | disclosed |
| EP-3969470-A1 | MESOTHELIN CARS AND USES THEREOF | Memorial Sloan Kettering Cancer Center (US) | 2022-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007750-A1 | CELLS AND COMPOSITIONS FOR TREATING CANCER | ICOS, MICA, CD47 | NPY1R 275/4885NPY2R 539/4885NPY4R 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.